Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SPRB

Spruce Biosciences Inc

Dec 11 • 04:00PM ET

88.41

+2.74 3.20 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-84.76	Insider Own	15.67%	Shs Outstand	1.07M	Perf Week	-2.24%
Market Cap	94.63M	Forward P/E	-	EPS next Y	-28.18	Insider Trans	-0.00%	Shs Float	0.90M	Perf Month	-21.52%
Enterprise Value	85.31M	PEG	-	EPS next Q	-5.47	Inst Own	31.06%	Short Float	11.34%	Perf Quarter	612.98%
Income	-47.88M	P/S	135.19	EPS this Y	86.22%	Inst Trans	1.10%	Short Ratio	0.18	Perf Half Y	1421.03%
Sales	0.70M	P/B	9.25	EPS next Y	-111.40%	ROA	-119.08%	Short Interest	0.10M	Perf YTD	180.67%
Book/sh	9.56	P/C	8.87	EPS next 5Y	23.98%	ROE	-167.93%	52W High	240.00 -63.16%	Perf Year	118.62%
Cash/sh	9.97	P/FCF	-	EPS past 3/5Y	10.79% -16.93%	ROIC	-813.44%	52W Low	4.28 1968.07%	Perf 3Y	6.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.41%	Volatility	12.00% 14.48%	Perf 5Y	-95.95%
Dividend TTM	-	EV/Sales	121.87	EPS Y/Y TTM	-17.93%	Oper. Margin	-7100.00%	ATR (14)	13.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.54	Sales Y/Y TTM	-90.18%	Profit Margin	-6869.30%	RSI (14)	44.50	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.54	EPS Q/Q	7.37%	SMA20	-10.09%	Beta	3.62	Target Price	209.50
Payout	-	Debt/Eq	0.25	Sales Q/Q	-100.00%	SMA50	-23.60%	Rel Volume	0.13	Prev Close	85.67
Employees	21	LT Debt/Eq	0.09	Earnings	Nov 10 AMC	SMA200	137.86%	Avg Volume	564.23K	Price	88.41
IPO	Oct 09, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-4.63% -	Trades		Volume	71,486	Change	3.20%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform	$160
Oct-28-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$254

Nov-10-25 04:05PM	Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (Business Wire) -8.97%
Oct-15-25 12:00PM	What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? (Zacks) -10.09%
Oct-08-25 08:00AM	Spruce Biosciences Announces $50.0 Million Private Placement Financing (Business Wire) -12.34%
Oct-07-25 09:44AM	This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. (Barrons.com) +40.03%
Oct-06-25 05:04PM	Why Spruce Biosciences Just Skyrocketed Almost 1,400% (Investor's Business Daily) +1,378.46%
08:00AM	Loading…
08:00AM	Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire)
Sep-15-25 07:00AM	Spruce Biosciences Resumes Trading on the Nasdaq Capital Market (Business Wire) -20.97%

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gharib Samir M.	PRESIDENT AND CFO	Oct 20 '25	Option Exercise	0.00	2,053	0	6,727	Oct 22 04:15 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Oct 20 '25	Option Exercise	0.00	4,784	0	11,013	Oct 22 04:15 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 08 08:55 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 08 08:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRB

Spruce Biosciences Inc

Upgrade your FINVIZ experience